Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | Q9HBH1 | 1/20 | 0.38 | |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17178689 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL18391329 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL12442419 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL3205376 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL12436525 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL12441917 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| Water SCHEMBL30811226 | 0.99 | FAP (0.43) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL15189371 | 0.97 | FAP (0.41) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL29983999 | 0.96 | FAP (0.41) | FAPHTR2APDFSSTR3ALDH1A1 | |
| SCHEMBL23493270 | 0.96 | HTR2A (0.43) | FAPHTR2APDFMAP1LC3BSSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026077418-A9 | ISOINDOLINE COMPOUND CONTAINING PHENYLETHOXYALKYLENEAMINE STRUCTURE, CONJUGATE THEREOF, AND USE THEREOF | 上海海雁医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4692115-A1 | ANTIBODY-FUNCTIONAL SUBSTANCE CONJUGATE, ANTIBODY DERIVATIVE, AND COMPOUND, OR SALTS THEREOF | AJINOMOTO CO., INC. (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-4692104-A1 | CONJUGATE OF ANTIBODY AND FUNCTIONAL SUBSTANCE OR SALT OF SAID CONJUGATE, AND ANTIBODY INTERMEDIATE HAVING THIOL GROUP OR SALT OF SAID ANTIBODY INTERMEDIATE | AJINOMOTO CO., INC. (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250367314-A1 | LINKER-PAYLOAD, AN ANTIBODY-DRUG CONJUGATE MADE THEREBY AND USES THEREOF | Chien, Du-Shieng (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20150165063-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | AUCKLAND CANCER SOCIETY RESEARCH CENTRE (NZ) | 2015-06-18 | — | — | US | disclosed |
| US-20150051380-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | GENENTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| EP-2303332-B1 | ANTHRACYCLINE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | GENENTECH INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140356375-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-8900589-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENETECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-8389697-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENENTECH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120130059-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | BERIA ITALO (IT) | 2012-05-24 | — | — | US | disclosed |
| US-20100034837-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | FAP 4493/4885HTR2A 3707/4885PDF 2043/4885 |
| US-20150165063-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | IDO1, DBI, IDO2 | FAP 3227/4885HTR2A 81/4885PDF 2971/4885 |
| US-20250367314-A1 | LINKER-PAYLOAD, AN ANTIBODY-DRUG CONJUGATE MADE THEREBY AND USES THEREOF | CD47, BCR, NQO2 | FAP 2428/4885HTR2A 1845/4885PDF 612/4885 |
| US-20140315954-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, CCNB2, CCNB3 | FAP 4380/4885HTR2A 4034/4885PDF 691/4885 |
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | CBLB, CBL, CBLC | FAP 4185/4885HTR2A 4024/4885PDF 3195/4885 |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | FAP 4493/4885HTR2A 3707/4885PDF 2043/4885 |
| US-20140356375-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885HTR2A 4166/4885PDF 581/4885 |
| US-20150051380-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | MRPL21, BCR, MYD88 | FAP 2195/4885HTR2A 4633/4885PDF 55/4885 |
| US-20140356376-A1 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES | STT3A, STT3B, DDOST | FAP 4221/4885HTR2A 4166/4885PDF 581/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | FAP 4480/4885HTR2A 1504/4885PDF 4492/4885 |
| US-20100034837-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | MRPL21, BCR, MYD88 | FAP 2195/4885HTR2A 4633/4885PDF 55/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | FAP 3962/4885HTR2A 4369/4885PDF 1120/4885 |
| US-20120130059-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | MRPL21, BCR, MYD88 | FAP 2195/4885HTR2A 4633/4885PDF 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.